Wellington Management Group LLP Sells 25,361 Shares of Twist Bioscience Corporation $TWST

Key Points

• Wellington Management Group LLP reduced its holdings in Twist Bioscience Corporation by 3.2%, bringing its total ownership to approximately 1.27%, valued at about $29.9 million.
• Insider selling was reported, with CEO Emily M. Leproust and CFO Adam Laponis selling shares, leading to a decrease in their ownership by 0.26% and 2.31%, respectively.
• Analyst opinions vary, with nine analysts giving a "Buy" rating, while the average target price for the stock is currently $49.40.

Wellington Management Group LLP reduced its holdings in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 3.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 760,951 shares of the company's stock after selling 25,361 shares during the quarter. Wellington Management Group LLP owned approximately 1.27% of Twist Bioscience worth $29,875,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TWST. First Light Asset Management LLC acquired a new position in Twist Bioscience in the 4th quarter valued at approximately $56,984,000. Nuveen LLC acquired a new position in Twist Bioscience in the 1st quarter valued at approximately $31,960,000. ARK Investment Management LLC increased its position in Twist Bioscience by 11.5% in the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock valued at $245,045,000 after acquiring an additional 645,730 shares during the period. Citigroup Inc. increased its position in Twist Bioscience by 124.1% in the 1st quarter. Citigroup Inc. now owns 206,461 shares of the company's stock valued at $8,106,000 after acquiring an additional 114,338 shares during the period. Finally, Lord Abbett & CO. LLC acquired a new position in Twist Bioscience in the 1st quarter valued at approximately $3,977,000.

Insider Buying and Selling at Twist Bioscience

In related news, CFO Adam Laponis sold 2,449 shares of the stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the transaction, the chief financial officer directly owned 103,569 shares of the company's stock, valued at $3,951,157.35. This represents a 2.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 1,678 shares of the firm's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $35.76, for a total transaction of $60,005.28. Following the completion of the transaction, the chief executive officer directly owned 645,782 shares in the company, valued at $23,093,164.32. This trade represents a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,250 shares of company stock worth $193,852. 3.01% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. JPMorgan Chase & Co. decreased their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Evercore ISI set a $46.00 price objective on shares of Twist Bioscience in a research report on Monday, August 4th. Guggenheim reiterated a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday, May 6th. The Goldman Sachs Group decreased their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Finally, Robert W. Baird decreased their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of "Moderate Buy" and a consensus price target of $49.40.

Twist Bioscience Stock Up 1.4%

NASDAQ TWST traded up $0.38 on Friday, hitting $26.97. 1,199,807 shares of the company were exchanged, compared to its average volume of 1,965,673. The company has a market cap of $1.63 billion, a PE ratio of -18.60 and a beta of 2.36. Twist Bioscience Corporation has a 12 month low of $24.28 and a 12 month high of $55.33. The stock has a fifty day moving average of $32.75 and a 200-day moving average of $35.53. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. The business had revenue of $96.06 million for the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.